Pinto Cathy A, Stafford Jeanette M, Wang Tongtong, Shankar R Ravi, Lawrence Jean M, Kim Grace, Pihoker Catherine, D'Agostino Ralph B, Dabelea Dana
Department of Pharmacoepidemiology, Merck & Co., Inc., Kenilworth, New Jersey.
Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Pediatr Diabetes. 2018 Sep;19(6):1065-1072. doi: 10.1111/pedi.12691. Epub 2018 Jun 13.
The aim of this study was to describe recent medication patterns and changes in medication patterns and glycemic control in adolescents and young adults with incident type 2 diabetes (T2D).
Using data from the SEARCH for Diabetes in Youth Study, we conducted a cross-sectional analysis of treatments for adolescents and young adults with incident T2D in 2 periods (2002-2005 vs 2008/2012), and a longitudinal analysis of medications and glycemic control for a subset with baseline and follow-up visits. Comparisons were performed using χ , Fisher's exact, or ANOVA.
Of 646 individuals in the cross-sectional analysis, a majority in each period received metformin (64.9% vs 70.4%) and/or insulin (38.1% vs 38.4%), while fewer used sulfonylureas (5.6% vs 3.6%) with non-significant changes over time. There was a significant reduction in thiazolidinedione use (5.0% vs 2.0%, P < .05). In the longitudinal analysis, 322 participants were followed for 7 years, on average. Baseline metformin users had a lower A1C (6.4% [46.7 mmol/mol]) compared to insulin (8.4% [68.2 mmol/mol], P < .001) or insulin plus any oral diabetes medication (ODM) users (7.7% [60.4 mmol/mol], P < .001). Among baseline metformin users (n = 138), 29.7% reported metformin at follow-up, with the remainder adding (19.6%) or switching to insulin (8.0%), ODM (15.9%), or lifestyle only (26.8%). Of those receiving insulin (±ODM) (n = 129), 76% reported insulin use at follow-up. Overall, 35% were at A1C goal (<7.0%, 53 mmol/mol) at follow-up.
Youth-onset T2D is still largely being treated with metformin and/or insulin. The majority treated were not at American Diabetes Association (ADA)-recommended goal 7 years after diagnosis.
本研究旨在描述初发2型糖尿病(T2D)青少年和青年的近期用药模式、用药模式变化及血糖控制情况。
利用青少年糖尿病研究(SEARCH for Diabetes in Youth Study)的数据,我们对初发T2D青少年和青年在两个时期(2002 - 2005年与2008/2012年)的治疗进行了横断面分析,并对一部分有基线和随访就诊的患者进行了药物治疗和血糖控制的纵向分析。使用卡方检验、Fisher精确检验或方差分析进行比较。
在横断面分析的646名个体中,每个时期大多数患者接受二甲双胍治疗(64.9%对70.4%)和/或胰岛素治疗(38.1%对38.4%),而使用磺脲类药物的患者较少(5.6%对3.6%),且随时间变化无显著差异。噻唑烷二酮类药物的使用显著减少(5.0%对2.0%,P < 0.05)。在纵向分析中,平均对322名参与者进行了7年的随访。与胰岛素使用者(8.4% [68.2 mmol/mol],P < 0.001)或胰岛素加任何口服降糖药(ODM)使用者(7.7% [60.4 mmol/mol],P < 0.001)相比,基线使用二甲双胍的患者糖化血红蛋白(A1C)较低(6.4% [46.7 mmol/mol])。在基线使用二甲双胍的患者(n = 138)中,29.7%在随访时仍报告使用二甲双胍,其余患者增加使用(19.6%)或改用胰岛素(8.0%)、ODM(15.9%)或仅改变生活方式(26.8%)。在接受胰岛素(±ODM)治疗的患者(n = 129)中,76%在随访时仍报告使用胰岛素。总体而言,35%的患者在随访时达到了A1C目标(<7.0%,53 mmol/mol)。
青少年起病的T2D仍主要用二甲双胍和/或胰岛素治疗。大多数接受治疗的患者在诊断7年后未达到美国糖尿病协会(ADA)推荐的目标。